Year: 2025
Type: article
Abstract: Site-directed RNA editing is a promising and potentially safer alternative to genome editing. Previous methods have been developed that recruit the endogenously and ubiquitously expressed ADAR enzymes to initiate site-specific A-to-I edits, but often suffer from low efficacy or dependency on viral delivery. Chemically modified oligonucleotides may be a promising alternative, but the approach still lacks systematic in-depth studies. Furthermore, the best characterized platform uses stereo-pure backbone chemistry, which is not widely used, commercially unavailable and challenging to manufacture. Here, we report on single-stranded oligonucleotides of 30-60 nt length, which are fully chemically stabilized by applying commercially available, classical RNA drug modifications, like 2´-O-methyl, 2´-fluoro, and DNA on a stereo-random phosphate/phosphorothioate backbone. We demonstrate our so-called RESTORE 2.0 oligonucleotides to induce the correction of pathogenic point mutations, efficacy after GalNAc-mediated uptake into human primary hepatocytes, and proof of in-vivo efficacy in mice upon lipid nanoparticle-mediated delivery. The discovered design principles may increase the accessibility of site-directed RNA base editing to expand and support further research in this field.
Source: Nature Communications
Authors: Laura S. Pfeiffer, Tobias Merkle, Paul Vogel, Inga Jarmoskaite, Jonathan M. Geisinger, Ngadhnjim Latifi, Marco Herrera-Barrera, Feijie Zhang, Lisa Groß, Carolin Schlitz, Daniel T. Hofacker, Clemens Lochmann, Davide Fumagalli, Stefanie Gackstatter, Vanessa Deisling, Mark A. Kay, Jin Billy Li, Thorsten Stafforst
Language: English
Topic: RNA regulation and disease
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funders: Deutsche Forschungsgemeinschaft, Eberhard Karls Universität Tübingen, Deutsche Akademie der Naturforscher Leopoldina - Nationale Akademie der Wissenschaften, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Awards: G1821385255, G2532469498, G3092341266, G3661049363, G7578079922, G8541508199, Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases, Regulatory and Mechanistic Understanding of ADAR-Mediated RNA Editing, EXC 2180: Individualisierung von Tumortherapien durch molekulare Bildgebung und funktionelle Identifizierung therapeutischer Zielstrukturen (iFIT), G985360846
OpenAlex ID: W4414787133
